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Edited by Robert BaroukiAbstract The metabolic syndrome is a cluster of cardiovascular
risk factors, and visceral adiposity is a central component that is
also strongly associated with insulin resistance. Both visceral
obesity and insulin resistance are important risk factors for the
development of type 2 diabetes. It is likely that adipose tissue,
particularly in the intra-abdominal depot, is part of a complex
interplay involving several tissues and that dysregulated hor-
monal, metabolic and neural signalling within and between or-
gans can trigger development of metabolic disease. One
attractive hypothesis is that many factors leading to insulin resis-
tance are mediated via the generation of abnormal amounts of
reactive oxygen species (ROS). There is much evidence support-
ing that detrimental eﬀects of glucose, fatty acids, hormones and
cytokines leading to insulin resistance can be exerted via such a
common pathway. This review paper mainly focuses on meta-
bolic and other ‘stress’ factors that aﬀect insulin’s target cells,
in particular adipocytes, and it will highlight oxidative stress
as a potential unifying mechanism by which these stress factors
promote insulin resistance and the development and progression
of type 2 diabetes.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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type 2 diabetes
Stress can be seen as a broad concept comprising various
threats to the maintenance of the organism’s homeostatic pro-
cesses. There is currently much evidence that external and
internal stress factors are of importance in the development
of the metabolic syndrome and type 2 diabetes [1]. Such stress
factors are found at a multitude of levels including the socio-
economic, psychological, neuroendocrine, metabolic andAbbreviations: FFA, free fatty acids; IL, interleukin; IRS, insulin
receptor substrate; JNK, c-Jun NH(2)-terminal kinase; MAPK,
mitogen-activated protein kinase; NFjB, nuclear factor kappa B;
PKC, protein kinase C; ROS, reactive oxygen species; TNF, tumour
necrosis factor
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cellular accumulation of reactive oxygen species (ROS) has
been implicated in atherosclerosis, microvascular complica-
tions of diabetes as well as in beta cell failure in type 2 diabetes
[2,3]. Emerging evidence also support an important role of
ROS in various forms of insulin resistance [4,5].
Type 2 diabetes is in most cases caused by a combination of
beta cell dysfunction and insulin resistance. Physical inactivity,
adiposity due to overeating, stress and smoking are risk factors
that interact with susceptibility genes in the development of the
disease. The metabolic syndrome is often used to deﬁne a clus-
ter of risk markers that predict cardiovascular disease but also
type 2 diabetes. Accumulating evidence suggest that abdomi-
nal obesity is a central component of this syndrome, that also
include hypertension, dyslipidemia, and glucose dysregulation
[6]. Insulin resistance is proposed as a major underlying cause
of many of the components of the metabolic syndrome. How-
ever, there is no consensus in that respect, and, moreover, it is
diﬃcult to envisage visceral obesity as a direct consequence of
insulin resistance, as insulin per se will promote lipid accumu-
lation in adipose tissue.
Nonetheless, insulin resistance appears to be an important
component of the complex pathophysiological processes that
underlies the development of type 2 diabetes and potentially
other associated conditions such as dyslipidemia, hypertension
and atherosclerosis. Insulin resistance can be deﬁned as an
attenuated eﬀect of insulin in target tissues, mainly muscle,
fat and liver [7]. In muscle, insulin-stimulated transmembrane
glucose uptake appears to be the major rate-limiting defect. In
adipose tissue, insulin resistance is manifested as impaired glu-
cose uptake and utilisation but in many cases also as an im-
paired suppression of lipolysis and release of free fatty acids
(FFA) and, in addition, it can also lead to dysregulated pro-
duction and secretion of adipokines and other adipose-derived
biomolecules. In the liver, there is attenuated insulin action
with respect to glucose uptake and storage as well as suppres-
sion of glucose and very low density-lipoprotein (VLDL) pro-
duction. Interestingly, there can also be insulin resistance in
the insulin-secreting beta cells of the endocrine pancreas and
this can be of importance in type 2 diabetes, leading to a atten-
uation of proinsulin synthesis and hence capacity for insulin
secretion. Stress mechanisms can be translated into risk of type
2 diabetes and metabolic syndrome partly via the insulin resis-
tance pathway, but obviously there can also be other routes
that directly aﬀect the function of, for example, pancreatic beta
cells and vascular endothelial cells [1]. The complex interplayblished by Elsevier B.V. All rights reserved.
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and the metabolic syndrome is schematically depicted in Fig. 1.
Although much eﬀort has been made to elucidate the pri-
mary mechanisms responsible for the development of insulin
resistance in the metabolic syndrome and type 2 diabetes, there
is no consensus at present. Obviously, there is much evidence
supporting the importance of genetic factors in human insulin
resistance [8]. There are common polymorphisms that are asso-
ciated with type 2 diabetes and/or insulin resistance, for exam-
ple in the genes for the transcription factor TCF7L2, calpain-
10, PGC-1a (a coactivator af the peroxisome proliferator-acti-
vated receptor gamma, PPARc), PPARc itself, insulin recep-
tor substrate 1 (IRS-1) and b-adrenergic receptors and
glycogen synthase. However, the quantitative impact of indi-Hyperglycemia
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One obvious hypothesis on the cause of insulin resistance is
that there would be a primary defect, inherited or acquired,
occurring in the signalling or eﬀector systems within insulin’s
targets cells. A schematic summary of the normal signalling
system that propagate insulin’s metabolic actions in target cells
is presented in Fig. 2. Perturbations could occur anywhere
along these signaling cascades as well as in alternate routes,
e.g. via lipid raft/TC 10 and MAP-kinase pathways, that
may be involved in metabolic as well as other eﬀects of insulin
[9]. Severe mutations aﬀecting components of the cellular insu-
lin-signalling machinery will certainly cause marked insulin
resistance, but such defects are very rare and are not found
in the common patients with the metabolic syndrome or type
2 diabetes. Instead, there is much evidence suggesting that cel-
lular insulin resistance is not a critical primary phenomenon in
the development of whole-body insulin resistance. For exam-
ple, prediabetic subjects can display essentially normal cellular
insulin sensitivity, and in insulin’s target cells obtained from
type 2 diabetic patients, it seems that insulin resistance is lar-
gely reversible [10,11]. Thus, perturbations in the extracellular
environment may appear ﬁrst and they may lead to a second-
ary cellular insulin resistance in for example muscle and adi-
pose tissue. Such ‘tissue environment’ factors may involve
metabolic, neural and hormonal signals. With respect to ‘met-
abolic signalling’, it is well recognized that high levels of glu-
cose and free fatty acids, that are hallmarks of type 2
diabetes, will have detrimental eﬀects in some tissues, e.g. mus-
cle and liver [12]. Moreover, hyperinsulinemia, occurring as a
compensatory mechanisms during development of type 2 dia-
betes, can in itself contribute to insulin resistance. A popular
concept in the etiology of type 2 diabetes and metabolic syn-
drome is that of intrauterine programming, suggesting that fe-
tal malnutrition leads to a risk for adult metabolic disease.
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‘imprinting’ in utero [13].
Although immense research eﬀorts have been made in order
to elucidate the mechanisms underlying insulin resistance,
there is still no concensus on the exact defects at the cellular
and molecular levels. There are several pathways that may
contribute to the development of insulin resistance and type
2 diabetes. Such pathways include metabolic factors, e.g. glu-
cose and fatty acids, that in elevated concentrations can extert
detrimental eﬀects. Neurohormonal mechanisms clearly can be
involved, and glucocorticoids, growth hormone, sex steroids
and catecholamines as well as insulin itself all have marked ef-
fects on insulin sensitivity in various tissues [14]. As visceral
adiposity appears to be a very important component of the
metabolic syndrome and also is a major risk factor for the
development of type 2 diabetes and cardiovascular disease,
adipose-related mechanisms are of interest. In adipose dys-
function, inﬂammatory mediators such as cytokines and che-
mokines as well as inﬂammatory cells, i.e. lymphocytes,
neutrophils and macrophages may play important roles.2. Metabolic stress – glucose, fatty acids and insulin
Regardless of the primary cause, when insulin resistance has
developed, insulin levels will rise in order to compensate for
the tendency of increase in circulating levels of glucose as well
as FFA. Normally, there are ﬁne-tuned feed-back loops to the
insulin-secreting b-cells to keep not only glucose but also FFA
levels within the physiological range. Once type 2 diabetes be-
comes established, the metabolic alterations will worsen and
they will per se aggravate insulin resistance and thus create a
vicious circle. In diabetes glucose levels are chronically ele-
vated and high insulin levels are detected early in the disease
but they then gradually fall as b-cell dysfunction progresses.
Experimental evidence suggest that hyperinsulinemia can
cause insulin resistance [15]. In addition, hyperglycaemia alone
exerts detrimental eﬀects on insulin secretion and insulin ac-
tion [16], a phenomenon commonly referred to as glucotoxic-
ity. In isolated human and rat adipocytes, long-term
exposure (several hours) to high glucose, particularly in the
presence of high insulin impairs insulin-activated glucose
transport capacity [17,18]. A common denominator for an im-
paired insulin action on glucose uptake in our studies on rat,
but not human, adipocytes seems to be a decrease in cellular
IRS-1 content [17,18]. Interestingly, low cellular IRS-1 gene
and protein expression has been reported to predict insulin
resistance and risk for type 2 diabetes [19], and individuals
with established type 2 diabetes have a marked reduction in
adipocyte IRS-1 protein expression and function whereas the
IRS-2 content is unaltered [19,20]. In both obesity and type
2 diabetes, there are high circulating FFA levels. They have
negative eﬀects on insulin sensitivity in muscle and liver, but
not consistently in fat cells [21,22]. Chronic elevation of FFAs
will also lead to an impairment of glucose-stimulated insulin
secretion in b-cells [23].
Our recent data suggest that IRS function rather than
amount, can be a critical mechanism for insulin resistance in
‘metabolic stress’ exerted by elevated insulin, glucose and pos-
sibly FFA levels. This is likely to be mediated via an altered
phosphorylation status of IRS-1, speciﬁcally an enhanced
Ser312 phosphorylation [24]. This impairs the interaction withother signaling proteins such as phosphatidyl inositol 3-kinase,
and it also appears to direct IRS-1 towards proteasome-medi-
ated degradation [24]. Probably, activation of protein kinase C
(PKC) isoforms that will increase IRS serine phosphorylation
is a critical intermediate mechanism for insulin resistance elic-
ited by glucotoxicity and lipotoxicity as well hyperinsulinemia
[25].
Obviously, neither high insulin, glucose or FFA levels are
expected to be primary causes of insulin resistance, but as sec-
ondary phenomena they may certainly contribute to cellular as
well as whole-body insulin resistance. One important mecha-
nism whereby hyperglycemia can induce insulin resistance, is
via cytokine release as has been shown in adipose cells [26].
Interestingly, high FFA levels, particularly in the portal vein,
can lead to central activation of the HPA axis and, in addition,
may elicit a sympathoadrenergic response [27]. Accordingly,
we observed that poor metabolic control in type 2 diabetic pa-
tients is associated with both elevated cytokine and cortisol
levels in the circulation [28].3. Neuroendocrine stress
There are several insulin-antagonistic hormones that play an
important role in situations of urgent need for extra fuel deliv-
ery to tissues, in prolonged fasting and in the defence against
spontaneous or drug-induced hypoglycemia. Such hormones
include glucagon, adrenaline, noradrenaline, growth hormone
and cortisol [12]. The ability to increase blood glucose will,
however, be a disadvantage when there is an inappropriate ele-
vation of such hormones. diabetes. In this context, the HPA
axis controlling adrenal cortisol secretion and the sympa-
thoadrenergic system have received most attention as path-
ways that can promote insulin resistance and development of
type 2 diabetes. These two pathways originate from ‘stress cen-
ters’ in the hypothalamus where they also connect to and mod-
ulate each other [1]. Some previous results suggest elevated
activities in both these systems in individuals with the meta-
bolic syndrome, and this has been proposed to be linked to
behavioral factors [29].
Cushing’s syndrome, i.e the clinical syndrome of glucocorti-
coid excess, is associated with insulin resistance, glucose intol-
erance, central obesity and hypertension. Pharmacological
treatment with high doses of glucocorticoids also leads to an
impairment of insulin sensitivity. In obesity the local conver-
sion of cortisone to cortisol within adipose tissue, via the
enzyme 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD-
1), appears to be elevated, and this can contribute to perturba-
tions in glucose and lipid metabolism as well as to adiposity it-
self [30]. The insulin-antagonistic eﬀects of glucocorticoids
include both an impairment of insulin-dependent glucose up-
take in peripheral tissues and a stimulation of gluconeogenesis
in the liver. It seems that there are direct cellular eﬀects leading
to an impairment of glucose transport, and dexamethasone-in-
duced insulin resistance in fat cells probably involves the glu-
cose transporter 4 (GLUT4) translocation process [12]. Data
from our research suggest that the impairment of glucose
transport in human omental fat cells might be attributed to de-
fects in the insulin-signaling pathway since cellular insulin
receptor substrate-1 (IRS-1) and protein kinase B (PKB) were
reduced by exposure to dexamethasone [31]. Part of the insu-
lin-antagonistic eﬀect of glucocorticoids appears to be second-
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levels. In addition, glucocorticoids may also inhibit insulin
secretion from pancreatic b-cells [32], and that may obviously
contribute to their diabetogenic properties.
Sympathetic nerve activity and the mediators, circulating
adrenaline and local tissue noradrenaline, exert profound inter-
actions with the metabolic eﬀects of insulin [12]. The autonomic
nervoussystemcanthus,mainlyviareleaseofcatecholamines,di-
rectly lead to tissue insulin resistance and, hence, promote devel-
opment of type 2 diabetes. In addition there are secondary eﬀects
since sympathoadrenergic activation will increase adipose tissue
lipolysisandtheresultingincrease incirculatingFFAlevelswill in
turn oppose insulin action in muscle and liver. Studies in animal
models of type 2 diabetes as well as patients with type 2 diabetes
have revealed an altered sympathetic activity and, moreover,
their carbohydrate metabolism seems abnormally sensitive to
sympathetic stimulation [12]. In healthy subjects, insulin resis-
tanceappears tobeassociatedwithanalteredbalance in theauto-
nomic nervous system with a relative increase in sympathetic vs
parasympatheticactivityfollowingstandardisedstress [33]orfol-
lowing hyperinsulinemia [34]. Insulin-resistant subjects seem to
have an attenuated response in the parasympathetic nervous sys-
tem upon standardised stimuli [33]. Thus, dysregulation of the
autonomic nervous systemmight be apotentialmechanism lead-
ing to insulin resistance and promoting the development of met-
abolic syndrome and type 2 diabetes.
The renin–angiotensin system (RAS) can also be an impor-
tant neuroendocrine pathway contributing to the development
of insulin resistance [33]. Renin is an enzyme that catalyses the
formation of angiotensin I from angiotensinogen, and then
angiotensin II is formed by the action of angiotensin convert-
ing enzyme (ACE). Angiotensin II has profound vascular ef-
fects in itself and it also stimulates aldosterone secretion
from the adrenal cortex. Overall eﬀects of RAS include vaso-
constriction, blood pressure elevation, renal eﬀects such as
ﬂuid and sodium retention and potassium excretion. But there
are also a multitude of other eﬀects in the CNS, skeletal mus-
cle, liver and adipose tissue. There appears to be eﬀects on
insulin sensitivity as antihypertensive medications that activate
RAS seem to cause insulin resistance whereas those that reduce
eﬀects of RAS, e.g. ACE inhibitors and angiotensin receptor
blockers (ARB), display a positive or neutral eﬀect on insulin
sensitivity [35]. In the adipose tissue it has been shown that a
local RAS can impair adipocyte recruitment and diﬀerentia-
tion, and that this can be prevented by ACE inhibitors or
ARBs [36]. Moreover, there seems to be a link between RAS
activity and inﬂammation within adipose tissue, and paracrine
eﬀects of angiotensin II are likely to be involved. The dominat-
ing regulation of circulating RAS activity is exerted via renin
production in the kidneys, that in turn is mainly regulated
by the sympathetic nervous system. Potentially, perturbations
in endocrine and paracrine RAS action can contribute to the
development of the metabolic syndrome, and they may also
channel external stress factors into metabolic dysregulation.4. Inﬂammatory stress
Previous studies have shown that elevated serum levels of C-
reactive protein (CRP) and several cytokines are associated
with obesity, insulin resistance and type 2 diabetes [14]. In theadipose tissue there is local production of TNF-a and interleu-
kin-6 both of which have potent insulin-antagonistic properties
that are ascribed to a direct interference with insulin signalling
[37]. These cytokines also have the potential to activate lipoly-
sis, and moreover it has been indicated that TNF-a inhibits
adiponectin production. Interestingly, an interaction between
TNF-a levels and the cortisol system has also been implicated,
and TNF-a may promote the conversion of cortisone to corti-
sol in adipocytes by activation of 11b-HSD-1 [38]. Both TNF-a
and IL-6 can stimulate cortisol secretion, directly or via HPA
activation. Our recent data indicate that high TNF-a, but not
interleukin-6, levels are linked to insulin resistance in type 2 dia-
betic individuals and that high levels of both cytokines are asso-
ciated with hyperglycemia [28]. Therefore, it might be suggested
that in the hyperglycemic state, TNF-a is a factor that contrib-
utes to insulin resistance, and this can occur partly via increased
cortisol levels. We also found that CRP levels were higher in
poorly controlled than in well-controlled type 2 diabetic pa-
tients. CRP levels were strongly correlated to glycemic level,
but surprisingly not to insulin resistance. These results suggest
that hyperglycemia per se is an important factor that contrib-
utes to the previously reported increase in CRP in type 2
diabetes and prediabetes [28]. Thus, in type 2 diabetes, hyper-
glycemia could lead to insulin resistance partly via an inﬂam-
matory response in adipose tissue as reﬂected by release of
cytokines into the circulation.5. Adipose tissue as a target for stress factors
There are now several studies that link psychosocial factors
to visceral adiposity, metabolic syndrome and type 2 diabetes.
Stressful life events and also low educational level are associ-
ated with risk for type 2 diabetes in the general population.
In women, work stress, low sense of coherence, and low emo-
tional support and, in men, sleeping disorders are stress factors
that have been associated with development of type 2 diabetes
[12]. Stressful situations will lead to neuroendocrine responses,
that in the long-term perspective might be important in the
development of visceral adiposity and type 2 diabetes. The
HPA axis together with the sympathetic nervous system can
mediate eﬀects of perceived stress in diﬀerent organs. The
downstream hormones of the sympathoadrenergic system
and the HPA axis, i.e. adrenaline, noradrenaline and cortisol,
respectively, are known to oppose the eﬀects of insulin. How-
ever, there are not much data available that demonstrate al-
tered levels of these hormones in individuals exposed to a
high psychosocial stress level. Some studies suggest elevated
cortisol levels in situations such as work stress and unemploy-
ment [39], and this is expected to lead to accumulation of
abdominal fat. On the contrary, subjects with metabolic syn-
drome and abdominal obesity have been reported to have a de-
creased diurnal variability but not an overall change in cortisol
levels [40]. Interestingly, in one study ACTH stimulation in-
duced an attenuated adrenocortical response measured as peak
serum cortisol in individuals with a family history of type 2
diabetes patients [41]. Bjo¨rntorp and coworkers proposed that
a hypothalamic arousal leads to insulin resistance and visceral
obesity via excess cortisol production, but at a later stage there
might be a shift to a ‘‘burn-out’’ phenomenon with low secre-
tion of cortisol, growth hormone and sex steroids [1,42].
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visceral obesity, and features of the metabolic syndrome. The
causal relationship is not established, but the association of
visceral fat accumulation in the development of insulin resis-
tance and type 2 diabetes has been generally accepted [40]. A
link between central obesity and HPA axis dysregulation has
also been suggested, and it is proposed that high glucocorti-
coid levels will promote lipid storage in visceral rather than
subcutaneous adipose tissue. Moreover, an altered balance in
the activity of the sympathetic and parasympathetic nervous
systems, respectively, appears to be associated with visceral
obesity [41]. Interestingly, in humans visceral adipose tissue
seems to have a greater propensity for inﬂammation than sub-
cutaneous adipose tissue, as evidenced by both higher levels of
cytokines as well as more resident macrophages [43]. Visceral
compared to subcutaneous adipocytes are more sensitive to
the lipolytic eﬀects of catecholamines, and to the insulin-antag-
onistic action of glucocorticoids, but they less sensitive to the
antilipolytic and lipogenic eﬀects of insulin [44]. In visceral adi-
posity, this could, in turn, result in diverting fatty acids to
other tissues, e.g. muscle and liver.
An interesting hypothesis is that of ‘adipose tissue overﬁll’.
In situations of excess energy intake, excess calories will be
stored primarily in adipose tissue. The best place for this is
the subcutaneous adipose depot, where fat accumulation does
not do much harm. In a situation of chronic calorie overload,
however, subcutaneous adipose tissue eventually reaches its
upper limit for further triglyceride storage, and this may trig-
ger adipose inﬂammation as well as lipid ‘spill-over’. This
means that energy storage will be partitioned towards the vis-
ceral fat depot and subsequently into ectopic fat depots, i.e,
intrahepatocellular and intramyocellular lipids (IHCL and
IMCL), both of which will have direct negative eﬀects on insu-
lin action in these tissues [45]. The capacity for fat storage in
subcutaneous adipose tissue could be determined by genetic
programming of recruitment of new adipocytes, but also by
neuroendocrine interactions as well as adipose inﬂammation.
A dysfunctional subcutaneous adipose tissue in this respect
may be an important cause of faulty deposition of lipids in
the intraabdominal and intramyocellular compartments. Inap-
propriate activity in the WNT-signalling system could have a
pivotal role in evoking this detrimental adipose phenotype,
e.g. by preventing adipogenesis as recently suggested by work
in the laboratory of U. Smith [46]. Interestingly, enlargement
of human fat cells can be taken as a sign of ﬁlled adipose en-
ergy stores, and it is independently associated with insulin
resistance both in vitro and in vivo [47].
It has been shown that an increased adipocyte size is associ-
ated with insulin resistance [47]. Furthermore, enlarged subcu-
taneous abdominal adipocytes can predict the development of
type 2 diabetes and this is partly independent of insulin resis-
tance [48]. Leptin and adiponectin are two adipocyte-speciﬁc
products that are secreted and eventually appear in the circu-
lation. Hyperleptinemia seems to be an independent marker
of fat cell hypertrophy, and leptin levels are also correlated
to the amount of body fat [47]. High leptin levels can thus
be seen as a reﬂection of the overﬁlled subcutaneous lipid
stores. Leptin has hypothalamic eﬀects leading to inhibition
of food intake and increased energy expenditure [49]. How-
ever, in peripheral tissues there are also direct insulin-antago-
nistic eﬀects that seem to be mediated via interactions with
the insulin signalling cascade, e.g. enhanced serine phosphory-lation of IRS-1 [50]. In contrast to leptin, the circulating levels
of adiponectin display inverse associations with insulin
resistance and body fat, and experimental data suggest that
adiponectin can reduce hyperglycemia, insulin resistance,
inﬂammation, atherosclerosis and potentially adiposity [51,52].
Increased secretion of adipokines, i.e. cytokine-like mole-
cules derived from adipose tissue, can partly explain why adi-
pocyte enlargement promotes insulin resistance [48]. Taken
together, substantial evidence support that fat cell size as well
as potential adipocyte-derived factors such as TNF-a, IL-6,
serum amyloid A, cortisol and FFAs are associated with insu-
lin resistance [47,53]. However, it should be appreciated that
circulating TNF-a and IL-6 do not mainly originate from adi-
pocyte tissue, and moreover, the main source of TNF-a within
adipose tissue is non-adipose cells [53].6. Oxidative stress – a common ﬁnal pathway in insulin
resistance?
Several types of insulin resistance appear to be linked to cel-
lular oxidative stress [5,54]. Oxidative stress indicates the intra-
cellular accumulation of reactive oxygen and nitrogen
compounds, mainly the so-called reactive oxygen species
(ROS). The major ROS variants are hydrogen peroxide
(H2O2), hypochlorous acid (HOCl), superoxide ðO2 Þ, hydr-
oxyl (OH), peroxyl ðRO2 Þ and hydroperoxyl ðHO2 Þ [5]. In
mitochondrial respiration, ROS are generated in the electron
transport chain, as a by-product in the ATP generating process
[3]. This occurs in situations of enhanced oxidation of energy
substrates such as glucose and FFA, unless uncoupling com-
pensates and prevents ROS formation. The enzyme NAD(P)H
oxidase plays a key role to stimulate ROS formation and it can
be activated by various cytokines. The mitochondrial mecha-
nisms involve increased levels of electron donors, mainly
FADH2 and NADH that are generated by the tricarboxylic
acid cycle, and they will push electrons into the protein com-
plexes of mitochondrial respiratory chain. This will lead to
electrons piling up in the mitochondrial electron transport
chain, and eventually they will be donated to molecular oxygen
generating superoxide, that subsequently can be degraded into
hydrogen peroxide by manganese superoxide dismutase [3].
Interestingly, excessive amounts of the ubiquitous biological
messenger nitrogen oxide (NO) appear to have detrimental ef-
fects that are similar to those of ROS. It has been reported that
NO production via inducible NO synthase (iNOS) is increased
in animal models of obesity and that deletion of the iNOS gene
(Nos2) can prevent diet-induced insulin resistance in skeletal
muscle [55].
Paradoxically, certain ROS may have insulin-mimicking ef-
fects, and for example hydrogen peroxide can increase trans-
membrane glucose transport and inhibit lipolysis [5].
Nonetheless, ROS accumulation in general is associated with
cellular insulin resistance, and this can occur through activa-
tion of stress kinases, injury to cellular membranes, the endo-
plasmic reticulum and nuclear DNA. Oxidative modiﬁcation
of cellular proteins and lipids may have functional conse-
quences that contribute to insulin resistance [5]. The detrimen-
tal cellular eﬀects of ROS are mediated by downstream eﬀector
mechanisms, but the details are poorly understood, and there
are probably diﬀerent mechanisms involved in diﬀerent cell
types and cellular functions. However, with respect to insulin
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nases, e.g. JNK, p38-MAPK, NFjB and certain PKC isoforms
are involved. A common denominator for these kinases seems
to be their ability to directly or indirectly increase serine/thre-
onine phosphorylation of IRS proteins, thus attenuation insu-
lin signalling. In addition, some of these kinases can increase
cytokine production, that also can impair insulin action.
There is now much emerging evidence that suggest that sev-
eral factors that cause insulin resistance have a common path-
way in the excessive formation of ROS [4,5,54]. This seems to
be true for inﬂammation, glucotoxicity, lipotoxicity and some
endocrine mediators. Fig. 3 summarises factors that may pro-
mote insulin resistance via ROS accumulation.
Inﬂammatory cytokines can increase oxidative stress, and
there are results suggesting that this can be mediated via cera-
mide formation that stimulates mitochondrial ROS produc-
tion. In adipose cells, TNF-a can thus increase ROS levels
that will activate the stress kinase JNK that in turn may in-
crease IRS-1 serine phosphorylation [5,54]. Antioxidant agents
given in the presence of TNF-a in vitro can prevent both insu-
lin resistance and oxidative stress. Antioxidant treatment of
insulin-resistant mice in vivo also leads to improvement of gly-
cemic control and insulin resistance [54]. Thus, there is strong
support for a pivotal role of ROS in cytokine-induced insulin
resistance [54].
Increased ﬂux of energy substrates into oxidative pathways
will lead to elevated activity of mitochondrial respiratory chain
and ROS generation. ROS accumulation could be seen as an
mitochondrial sensor of energy overﬂow into cells, and it
may act as a safeguard preventing further inﬂow and storage
of substrate. Thus, both high FFA and glucose levels will lead
to increased substrate oxidation and a secondary increase in
mitochondrial ROS formation [56]. In ‘overloaded’ adipocytes,
it is possible that an increase in intra-adipocyte fatty acid levels
will be accompanied by oxidative stress. This may partly ex-
plain the strong link between fat cell enlargement and insulin
resistance [47]. Clinical data also suggest that overall oxidative
stress is increased in subjects with visceral obesity [57].
Hyperglycemia-induced oxidative stress is likely to be of great
importance in diabetes, particularly in patients whose glucose is
poorly controlled. Importantly, further support is provided by a
study showing that hyperglycemia-induced insulin resistanceROS
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Fig. 3. ROS accumulation as a unifying pathway leading to and
insulin resistance. Several factors exerting cellular stress are proposed
to cause insulin resistance via increased ROS production and oxidative
stress.can be prevented by antioxidant treatment [58]. In addition,
there are data indicating that postprandial glucose peaks in type
2 diabetes, have a particular propensity to increase ROS forma-
tion in the vessel walls [59]. This can be of major importance for
the development of micro- and macrovascular diabetic compli-
cations. Taken together, there are data supporting that oxida-
tive stress is a critical mechanism both in glucotoxicity that
contributes to cellular insulin resistance as well as b-cell failure
and in the development of organ injuries that are associated
with chronic hyperglycemia and vascular dysfunction
[3,26,59]. In fairness, there are also data that suggest no increase
in oxidative stress in type 2 diabetes, e.g. in skeletal muscle [60].
In insulin’s target organs, such as adipose tissue and skeletal
muscle, glucotoxicity is thought to be mediated via the so-called
hexosamine pathway [11]. Together with oxidative stress it
could serve as a compensatory mechanism signalling that no
more fuel is needed and consequently attempting to downregu-
late insulin-mediated glucose uptake. On the other hand, in
other tissues such as nerves and blood vessels, where glucose
ﬂux is not insulin-dependent, there will be continuing glucose
overload and subsequently irreversible damage, i.e. chronic dia-
betic complications aﬀecting nerves, kidneys and the retina.
Interestingly, some neuroendocrine pathways leading to
insulin resistance also involves ROS formation in target cells.
It was recently reported that dexamethasone-induced insulin
resistance in adipose cells is associated with ROS formation
[54]. Interestingly, insulin resistance was avoided upon concom-
itant treatment with antioxidants as well as in cells with overex-
pression of ROS-metabolizing enzymes. With respect to RAS,
there is support for ROS involvement in some of the eﬀects
of angiotensin II that lead to inﬂammation and insulin resis-
tance, and ARBs seem to attenuate oxidative stress [61,62].
Smoking is another factor that is known to cause insulin
resistance and it is associated with risk for type 2 diabetes
development. The mechanisms involved are not deﬁned, but
they may include activation of the sympathetic nervous system,
altered levels of cytokines and endothelial dysfunction seem to
be of importance. Interestingly, smoking is also reported to in-
crease oxidative stress in diﬀerent cell types, and this can be an
important mechanism for insulin resistance as well as for ath-
erosclerosis in smokers [63].
There are some clinical studies addressing potential treat-
ments aiming at reduction of oxidative stress, and they have
mainly focused on treatment or prevention of cardiovascular
disease. In general, such programs have primarily tested anti-
oxidant vitamins and other potential ROS scavengers, and
the overall results have so far been disappointing with respect
to cardiovascular outcome. This is also true for the few trials
addressing metabolic control in type 2 diabetes. Clinical bio-
markers of oxidative stress have been applied in some studies,
and such markers include variants of lipids, lipoproteins, pros-
taglandin derivatives and amino acids that are modiﬁed by
ROS. However, such measures need more validation before
they can be generally recommended in large-scale studies or
in clinical practice.7. Conclusion
The mechanisms causing insulin resistance in type 2 diabetes
and the metabolic syndrome, are yet not fully understood. It is
generally accepted that a complex interplay between genetic
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Fig. 4. A hypothesis on the development of insulin resistance and type 2 diabetes over time. Various stress mechanisms challenge the organism’s
metabolic homeostasis. In a decompensated situation, where the total stressor load exceeds the capacity of compensatory mechanisms, oxidative
stress occurs at the cellular level and this leads to insulin resistance and eventually beta cell failure and vascular damage.
3740 J.W. Eriksson / FEBS Letters 581 (2007) 3734–3742and acquired factors is key in the pathobiology of these disor-
ders. It is likely that stressors in various forms hit the organism
at many diﬀerent levels and that this adds up to a pathogenic
process moving towards insulin resistance and diabetes. Such
stressors, i.e. social, psychological, neural, endocrine, meta-
bolic, inﬂammatory factors, may merge into a ﬁnal common
pathway namely oxidative stress at the cellular level. It is pro-
posed that this is a critical pathway for the development of
insulin resistance in insulin’s target tissues, but also for beta
cell dysfunction and macro- and microvascular damage in dia-
betes. A schematic summary of this hypothesis is depicted in
Fig. 4. Future research in the ﬁeld of metabolic diseases should
include elucidation of potential new mechanisms, biomarkers
and pharmacological targets related to ROS production as well
as downstream signals activated by ROS accumulation. This
would improve our understanding of the complex disease
mechanisms and facilitate development of new therapeutic ap-
proaches.Conﬂict of interest statement
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